05/11/2018 15:04:08

New Study Suggests Zika Virus Eradication in the Americas May Become Impossible, Making the Need for a Vaccine Even More Critical

GeoVax Comments on New Study Conducted in Brazil

ATLANTA, GA, Nov. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- 

GeoVax Labs, Inc

. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on a research article on Zika virus appearing in Scientific Reports. The new article, published by researchers from The University of Texas Medical Branch at Galveston and the Faculty of Medicine of Sao Jose do Rio in Brazil, describes the detection of Zika virus in dead monkeys found in several areas in Brazil.

Zika virus is spread among humans predominately via mosquitos. The discovery of Zika in dead primates raises concerns that the disease may have a “wild cycle” similar to yellow fever, whereby wild animals could become a “natural reservoir” from which the virus can re-infect the human population more frequently. This would make combatting Zika much more difficult than previously assumed, making complete eradication of the virus in the Americas very unlikely. 

David Dodd, GeoVax President & CEO, commented, “This study highlights the importance of a vaccine solution for Zika. Our vaccine candidate, GEO-ZM02, has demonstrated 100% single-dose protection in mice against a lethal dose of Zika virus, and is progressing to studies in non-human primates with funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). We have also initiated discussions with potential collaborators in Brazil in preparation for human clinical trials.”

Mr. Dodd continued, “GEO-ZM02 not only has the potential of a single-dose vaccine, which is practical for resource-strained countries, but also does not bear the risk of enhancing other flavivirus infections, such as Dengue, in vaccinated subjects. This phenomenon, called Antibody Dependent Enhancement (ADE) of infection, is a potential safety concern for other Zika vaccines under development that utilize the structural Envelope protein of Zika for their vaccine construct. GEO-ZM02 is based on the NS1 protein of Zika, which is not involved in ADE.”

About GeoVax

GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections.

GeoVax’s vaccine technology is based on its Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated. Gene sequences of target antigens are inserted into the MVA genome which drives their expression in infected cells. In addition, GeoVax introduces into the viral genome matrix sequences that incorporate antigens into VLPs and simultaneously facilitate their budding from the membranes of host cells. In this way, vaccination induces two pools of antigens as targets for the immune response – host cells and VLPs secreted from host cells. This strategy mimics a natural viral infection, triggering the body to produce a robust and durable immune response with involvement of both antibodies and T cells.  For more information, visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax’s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those under "Risk Factors" in its Form 10-K.

Contact: 

GeoVax Labs, Inc.

investor@geovax.com

678-384-7220

299982_GeoVaxLogo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Apr
I:SP500
  Hejsa.   Lige lidt læsestof til påsken.   Langsigtet konjunktur:   Overraskende stigning i de le..
48
18 Apr
 
Jeg har modtaget flg. fra Delfin : "Nå, så er jeg blokeret på EI. Hvorfor ved jeg ikke. Jeg har ikke..
37
17 Apr
VELO
  Den eneste TA-ekspert var for mig alpehue, og nogle ganske få andre. Langt de fleste, som udtaler ..
28
15 Apr
VELO
Solen skinner++Envarsus viser vejen med endnu engang rigtig gode data. https://www.ncbi.nlm.nih.gov..
24
17 Apr
 
EI hvorfor har I slettet mit indlæg 414414 og hele debatten om hvad en moderater bør blande sig i ? ..
21
20 Apr
NOVO-B
En lille påskehilsen fra Alpe, med mulighed for Novo.   https://invst.ly/al3nf  
20
21 Apr
NOVO-B
Det var bare mig, der havde spurgt Alpe om en streg på Novo, hvorefter jeg modtog dette, og gerne må..
16
17 Apr
TEVA
Den er også svær lige nu fordi mange korte og lange signaler krydser ind over hinanden lige nu. Men ..
11
15 Apr
VWS
Vestas i 600.. 😊 Det er en stor dag... Tillykke til de tålmodige og trofaste aktionærer.. Endelig ..
11
20 Apr
ZEAL
Nedenfor er en artikle fra Ritzau fra 2018 som gennemgår situationen med Zealand Pharmas tyske samar..
10

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sprint Corp. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 April 2019 01:55:05
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB6 - 2019-04-22 02:55:05 - 2019-04-22 01:55:05 - 1000 - Website: OKAY